Morningstar® Stock Report™

Novartis AG NOVN

Gewinnmarge (% des Umsatzes)
20192020202120222023
Ertrag100,00%100,00%100,00%100,00%100,00%
Betriebskosten29,63%30,30%30,01%29,88%26,73%
Bruttogewinn70,37%69,70%69,99%70,12%73,27%
Vertriebsgemeinkosten29,52%28,45%28,15%27,50%26,83%
Forschung und Entwicklung19,32%18,00%18,04%19,29%24,37%
Umsatzrendite18,67%20,35%22,11%17,75%20,94%
Net Int, Inc and Other37,03%40,14%71,54%33,90%40,49%
EBIT Marge18,37%19,80%49,43%16,15%19,55%
Ertragskraft
20192020202120222023
Steuersatz3,68%3,62%4,01%2,73%1,18%
Nettomarge24,10%16,18%45,43%13,42%31,83%
Gesamtkapitalrendite8,896,4518,215,5813,66
Financial Leverage2,132,331,951,982,14
Eigenkapitalsrendite17,5014,4138,6610,9528,02